Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 17/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.59 |
| ▸ | FAP | Q12884 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5646219 | 0.85 | DPP4 (0.62) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1378083 | 0.81 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL6824122 | 0.81 | DPP4 (0.84) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL6824549 | 0.81 | DPP7 (0.83) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL3403495 | 0.80 | DPP4 (0.77) | DPP4DPP8DPP7 | |
| Trifluoroacetic Acid SCHEMBL2400454 | 0.80 | DPP4 (0.77) | DPP4DPP8DPP7 | |
| Trifluoroacetic Acid SCHEMBL5203132 | 0.80 | DPP4 (0.84) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL5203128 | 0.80 | DPP4 (0.84) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL5696185 | 0.80 | DPP4 (0.84) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL5651865 | 0.79 | DPP4 (0.63) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169806-B2 | Antidiabetic agents | FERRING BV (NL) | 2007-01-30 | — | — | US | disclosed |
| US-20050203031-A1 | Novel antidiabetic agents | FERRING BV | 2005-09-15 | — | — | US | disclosed |
| US-6911467-B2 | Antidiabetic agents | FERRING BV (NL) | 2005-06-28 | — | — | US | disclosed |
| EP-1351932-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | Ferring BV (NL) | 2003-10-15 | — | — | EP | disclosed |
| US-20030096857-A1 | Novel antidiabetic agents | FERRING BV (NL) | 2003-05-22 | — | — | US | disclosed |
| WO-2001040180-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | FERRING BV (NL) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096857-A1 | Novel antidiabetic agents | DPP4, SLC5A2, SLC2A4 | DPP4 1/4885DPP8 44/4885DPP9 62/4885 |
| US-20050203031-A1 | Novel antidiabetic agents | DPP4, SLC2A4, GPR119 | DPP4 1/4885DPP8 155/4885DPP9 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.